<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biosci Microbiota Food Health</journal-id><journal-id journal-id-type="iso-abbrev">Biosci Microbiota Food Health</journal-id><journal-id journal-id-type="publisher-id">BMFH</journal-id><journal-title-group><journal-title>Bioscience of Microbiota, Food and Health</journal-title></journal-title-group><issn pub-type="ppub">2186-6953</issn><issn pub-type="epub">2186-3342</issn><publisher><publisher-name>BMFH Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26594607</article-id><article-id pub-id-type="pmc">4639512</article-id><article-id pub-id-type="publisher-id">2015-001</article-id><article-id pub-id-type="doi">10.12938/bmfh.2015-001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Full Paper</subject></subj-group></article-categories><title-group><article-title>Short- and long-term dynamics in the intestinal microbiota following ingestion of
<italic>Bifidobacterium animalis</italic> subsp. <italic>lactis</italic> GCL2505</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>TANAKA</surname><given-names>Yoshiyuki</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref rid="cor1" ref-type="corresp"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>TAKAMI</surname><given-names>Kazuyo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>NISHIJIMA</surname><given-names>Tomohiko</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>AOKI</surname><given-names>Ryo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>MAWATARI</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>IKEDA</surname><given-names>Takayuki</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><aff id="aff1"><label>1</label>Institute of Health Science, Ezaki Glico Co., Ltd., 4-6-5 Utajima,
Nishiyodogawa-ku, Osaka 555-8502, Japan</aff><aff id="aff2"><label>2</label>R&#x00026;D Division, Glico Dairy Products Co., Ltd., 2-14-1 Musashino, Akishima-shi,
Tokyo 196-0021, Japan</aff><aff id="aff3"><label>3</label>Faculty of Human Life Science, Fuji Women&#x02019;s University, 4-5 Hanakawaminami,
Ishikari-shi, Hokkaido 061-3204, Japan</aff></contrib-group><author-notes><corresp id="cor1">*Corresponding author. Mailing address: Yoshiyuki Tanaka, Institute of Health Science, Ezaki
Glico Co., Ltd., 4-6-5 Utajima, Nishiyodogawa-ku, Osaka 555-8502, Japan. Phone: +81-6-6477-8425, Fax:
+81-6-6477-8362. E-mail: <email xlink:href="tanaka-yoshiyuki@gd.glico.co.jp">tanaka-yoshiyuki@gd.glico.co.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>34</volume><issue>4</issue><fpage>77</fpage><lpage>85</lpage><history><date date-type="received"><day>21</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>10</day><month>7</month><year>2015</year></date></history><permissions><copyright-statement>BMFH Press</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution
Non-Commercial No Derivatives (by-nc-nd) License. </license-p></license></permissions><abstract><p><italic>Bifidobacterium animalis</italic> subsp. <italic>lactis</italic> GCL2505 (<italic>B. lactis</italic>
GCL2505) is able to survive passage through the intestines and proliferate. The daily dynamics of the
intestinal bifidobacteria following ingestion of probiotics are not yet clear. Moreover, the effects of
long-term ingestion of probiotics on the intestinal microbiota have not been well studied. Two experiments
were performed in the present study. In Experiment 1, 53 healthy female volunteers received <italic>B.
lactis</italic> GCL2505; <italic>B. bifidum</italic> GCL2080, which can survive but not proliferate in the
intestine; or yogurt fermented with <italic>Lactobacillus delbrueckii</italic> subsp.
<italic>bulgaricus</italic> and <italic>Streptococcus thermophilus</italic> for 2 weeks, and the daily
dynamics of intestinal bifidobacteria were investigated. The number of fecal bifidobacteria significantly
increased on day 1, and this was maintained until day 14 in the <italic>B. lactis</italic> GCL2505 ingestion
group. However, no significant change in the number of fecal bifidobacteria was observed in the other groups
throughout the ingestion period. In Experiment 2, 38 constipated volunteers received either <italic>B.
lactis</italic> GCL2505 or a placebo for 8 weeks. Both the number of fecal bifidobacteria and the frequency
of defecation significantly increased throughout the ingestion period in the <italic>B. lactis</italic>
GCL2505 ingestion group. These results suggested that the proliferation of ingested bifidobacteria within the
intestine contributed to a rapid increase in the amount of intestinal bifidobacteria and subsequent
maintenance of these levels. Moreover, <italic>B. lactis</italic> GCL2505 improved the intestinal microbiota
more effectively than non-proliferating bifidobacteria and lactic acid bacteria.</p></abstract><kwd-group><kwd>probiotics</kwd><kwd><italic>Bifidobacterium</italic></kwd><kwd>dynamics</kwd><kwd>intestinal microbiota</kwd><kwd>proliferation</kwd><kwd><italic>Bifidobacterium animalis</italic> subsp. <italic>lactis</italic> GCL2505</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>The human intestinal tract is normally inhabited by 400&#x02013;500 types of bacteria, and it harbors a large, active,
and complex community of microbes [<xref rid="r1" ref-type="bibr">1</xref>]. The intestinal microbiota play
several significant roles in the digestion of food, the metabolism of endogenous and exogenous compounds,
immunomodulation, and the inhibition of colonization by pathogenic bacteria, thus making them important for
maintaining human health [<xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r3" ref-type="bibr">3</xref>].
Members of genus <italic>Bifidobacterium</italic> are among the most predominant organisms in the human
intestine and are important for general health, which means that their diversity and number provides a marker
for measuring the stability of human intestinal microbiota, as well as the intestinal environment [<xref rid="r4" ref-type="bibr">4</xref>, <xref rid="r5" ref-type="bibr">5</xref>].</p><p>Probiotics are defined as &#x0201c;live microorganisms which when administered in adequate amounts confer a health
benefit on the host&#x0201d; (Food and Agriculture Organization of the United Nations/World Health Organization 2002).
Many studies have investigated the effects of probiotic consumption on intestinal microbial imbalance, on
suppression of pathogens and prevention and treatment of intestinal and other disorders, and on inflammatory
bowel disease, diarrhea, infection, colon cancer, constipation, and atopic diseases [<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref>]. In particular, numerous attempts have been made to increase the number of intestinal
bifidobacteria and improve intestinal disorders such as constipation and diarrhea through use of probiotics
[<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>]. In most of these studies, however, the numbers
of intestinal bifidobacteria were investigated using cultivation-based techniques [<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>], which are widely known to be labor-intensive and time-consuming. In
addition, classification and identification based on phenotypical traits do not always provide clear-cut results
and are sometimes unreliable because the recovery of bifidobacteria from feces depends on the composition of the
medium and the culture conditions [<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r18" ref-type="bibr">18</xref>]. Currently, 16S rRNA-targeted oligonucleotide probes are
used with fluorescent in-situ hybridization and genus- and species-specific PCR as a culture-independent method
[<xref rid="r19" ref-type="bibr">19</xref>,<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r23" ref-type="bibr">23</xref>].
These methods enable rapid and specific detection of a wide range of bacterial species. Genus-specific primers
or probes are expected to provide a good overall picture of the fecal bifidobacterial population, although there
are few reports describing the effect of probiotic administration on bifidobacterial composition, especially
those that focus on the daily dynamics of both endogenous and exogenous (ingested) bifidobacteria.</p><p><italic>Bifidobacterium animalis</italic> subsp. <italic>lactis</italic> (<italic>B. lactis</italic>) GCL2505
is a probiotic that originates from healthy human intestines and is used in fermented milk products in the
Japanese market. We previously showed that <italic>B. lactis</italic> GCL2505 reached the intestine in a viable
form and was subsequently able to proliferate after a single ingestion, which led to an increase in the amount
of intestinal bifidobacteria and more frequent defecation after 2 weeks of ingestion [<xref rid="r24" ref-type="bibr">24</xref>]. However, the daily dynamics of intestinal bifidobacteria at the species level following
ingestion of <italic>B. lactis</italic> GCL2505 are not yet clear. Moreover, the effects of long-term ingestion
of <italic>B. lactis</italic> GCL2505 on the composition of intestinal bifidobacteria and the changes in the
frequency of defecation lasting over 2 weeks have not been well studied. In this study, we compared the dynamics
of intestinal bifidobacteria after ingestion of <italic>B. lactis</italic> GCL2505 and other bifidobacteria that
can survive but not proliferate in the intestine, as well as those of lactic acid bacteria used in yogurt
fermentation. Quantitative real-time PCR using <italic>Bifidobacterium</italic> species- and subspecies-specific
primers were used to elucidate the daily dynamics of endogenous and ingested strains at the species level.
Moreover, we investigated the change in the intestinal microbiota and the frequency of defecation following
long-term ingestion.</p></sec><sec sec-type="methods" id="s2"><title>MATERIALS AND METHODS</title><sec><title>Test beverages</title><p>The test beverages included a milk-like drink, a yogurt drink, or a placebo drink (100 g of each). <italic>B.
lactis</italic> GCL2505 or <italic>B. bifidum</italic> GCL2080 was added to the milk-like drink. The viable
cell count of <italic>B. lactis</italic> GCL2505 or <italic>B. bifidum</italic> GCL2080 in a test beverage was
1.5 &#x000d7; 10<sup>10</sup> cfu or 2.6 &#x000d7; 10<sup>10</sup> cfu, respectively. The yogurt drink was fermented with
<italic>L. delbrueckii</italic> subsp. <italic>bulgaricus</italic> GCL1031 and <italic>S.
thermophilus</italic> GCL1122, both of which are commonly used in the production of conventional yogurt. The
viable cell count of lactic acid bacteria (<italic>L. bulgaricus</italic> and <italic>S.
thermophilus</italic>) in a test beverage was 3.0 &#x000d7; 10<sup>10</sup> cfu. The placebo drink was prepared with
the same ingredients as the milk-like drink and had a similar flavor but it did not contain bacteria.</p></sec><sec><title>Subjects and study design of a short-term trial (Experiment 1)</title><p>Sixty-four healthy female subjects were recruited (age range: 18&#x02013;25 years). These subjects claimed that they
had a frequency of bowel movements of &#x02265;5.0 times/week in a questionnaire performed in advance. The aim of
Experiment 1 was to elucidate the daily dynamics of intestinal microbiota; thus, subjects were required to
provide daily fecal samples. We therefore selected subjects who claimed in a preliminary questionnaire that
they had a frequency of bowel movements of &#x02265; 5.0 times/week.</p><p>The study was designed as a double-blind, parallel-group comparison and consisted of two consecutive 2-week
periods: a non-ingestion period and an ingestion period. Subjects were randomized and assigned into one of
three groups that received a test beverage containing either <italic>B. lactis</italic> GCL2505 (BL group),
<italic>B. bifidum</italic> GCL2080 (BB group), or <italic>L. bulgaricus</italic> GCL1031 and <italic>S.
thermophilus</italic> GCL1122 (LBST group). During the ingestion period, the subjects consumed one test
beverage daily. Each subject provided fecal samples for microbial analysis at the end of the non-ingestion
period and on days 1&#x02013;4, 7, and 14 of the ingestion period (<xref ref-type="fig" rid="fig_001">Fig.
1</xref><fig orientation="portrait" fig-type="figure" id="fig_001" position="float"><label>Fig. 1.</label><caption><p> Scheme of Experiment 1.</p></caption><graphic xlink:href="bmfh-34-077-g001"/></fig>). Subjects were instructed to avoid the intake of fermented milks, lactic acid bacteria beverages,
probiotic and prebiotic products, and fermented foods such as <italic>natto</italic> (soybean fermented with
<italic>B. subtilis</italic>) for the duration of the study.</p></sec><sec><title>Subjects and study design of a long-term trial (Experiment 2)</title><p>Forty-two mildly constipated female subjects were selected (age range: 25&#x02013;59 years). These subjects claimed
that they had a frequency of bowel movements of &#x02264;5.0 times/week in a questionnaire completed in advance.</p><p>The study took the form of a double-blind, parallel-group comparison and consisted of a 2-week non-ingestion
period in which initial parameters were obtained for baseline measurements, followed by an 8-week ingestion
period. During the ingestion period, subjects consumed 1 test beverage daily. Subjects were randomized and
assigned to two groups (active or placebo group). The active group consumed a test beverage containing
<italic>B. lactis</italic> GCL2505, and the placebo group consumed a test beverage without <italic>B.
lactis</italic> GCL2505. Each subject provided fecal samples for microbial analysis at the end of the
non-ingestion period and in weeks 2, 4, and 8 of the ingestion period and recorded their daily number of
defecations (<xref ref-type="fig" rid="fig_002">Fig. 2</xref><fig orientation="portrait" fig-type="figure" id="fig_002" position="float"><label>Fig. 2.</label><caption><p> Scheme of Experiment 2.</p></caption><graphic xlink:href="bmfh-34-077-g002"/></fig>). As in Experiment 1, subjects were instructed to avoid the intake of other fermented milks, lactic
acid bacteria beverages, probiotic and prebiotic products, and fermented foods such as <italic>natto</italic>
(soybean fermented with <italic>B. subtilis</italic>) for the duration of the study.</p></sec><sec><title>Determination of fecal microbiota</title><p>Fecal samples were delivered in a refrigerated, anaerobic state using an AnaeroPack Kenki (Mitsubishi GAS
Chemical Co., Inc., Tokyo, Japan), diluted 10-fold with phosphate-buffered saline (pH 7.4) and homogenized
using a Stomacher. Suspensions were kept at &#x02212;80&#x000b0;C until assayed.</p><p>Bacterial DNA was extracted from the 10-fold dilutions of fecal samples according to the procedure described
by Matsuki et al. [<xref rid="r25" ref-type="bibr">25</xref>]. The number of intestinal bifidobacteria was
quantified by real-time PCR using <italic>Bifidobacterium</italic> species- and subspecies-specific primers,
according to the procedure described by Ishizuka et al. [<xref rid="r24" ref-type="bibr">24</xref>]. Briefly,
PCR amplification and detection procedures were performed using a CFX-96 Real-Time PCR Detection System
(Bio-Rad Laboratories Inc., Hercules, CA, USA). Each reaction mixture (10 &#x000b5;l) was composed of 5 &#x000b5;l of SYBR
Premix Ex Taq I or II, 1 &#x000b5;l of each primer (<xref rid="tbl_001" ref-type="table">Table 1</xref><table-wrap id="tbl_001" orientation="portrait" position="float"><label>Table 1.</label><caption><title> The 16S rRNA gene-targeted primers used in this study</title></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" rowspan="1" colspan="1">Target</td><td align="center" rowspan="1" colspan="1">Primer</td><td align="center" rowspan="1" colspan="1">Sequence (5&#x02019;&#x02013;3&#x02019;)</td><td align="center" rowspan="1" colspan="1">Annealing temp (&#x000b0;C)</td><td align="center" rowspan="1" colspan="1">SYBR Premix Ex Taq</td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="2" colspan="1"><italic>B. bifidum</italic></td><td align="left" valign="top" rowspan="1" colspan="1">BiBIF-1</td><td align="left" valign="top" rowspan="1" colspan="1">CCACATGATCGCATGTGATTG </td><td align="center" valign="top" rowspan="2" colspan="1">55</td><td align="center" valign="top" rowspan="2" colspan="1">I</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BiBIF-2</td><td align="left" valign="top" rowspan="1" colspan="1">CCGAAGGCTTGCTCCCAAA</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><italic>B. breve</italic></td><td align="left" valign="top" rowspan="1" colspan="1">BiBRE-1</td><td align="left" valign="top" rowspan="1" colspan="1">CCGGATGCTCCATCACAC</td><td align="center" valign="top" rowspan="2" colspan="1">65</td><td align="center" valign="top" rowspan="2" colspan="1">II</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BiBRE-2</td><td align="left" valign="top" rowspan="1" colspan="1">ACAAAGTGCCTTGCTCCCT</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><italic>B. longum</italic></td><td align="left" valign="top" rowspan="1" colspan="1">BiLON-1</td><td align="left" valign="top" rowspan="1" colspan="1">TTCCAGTTGATCGCATGGTC</td><td align="center" valign="top" rowspan="2" colspan="1">63</td><td align="center" valign="top" rowspan="2" colspan="1">I</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BiLON-2</td><td align="left" valign="top" rowspan="1" colspan="1">GGGAAGCCGTATCTCTACGA</td></tr><tr><td align="left" valign="top" rowspan="3" colspan="1"><italic>B. adolescentis</italic></td><td align="left" valign="top" rowspan="1" colspan="1">BiADOg-1a</td><td align="left" valign="top" rowspan="1" colspan="1">CTCCAGTTGGATGCATGTC</td><td align="center" valign="top" rowspan="3" colspan="1">63</td><td align="center" valign="top" rowspan="3" colspan="1">I</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BiADOg-1b</td><td align="left" valign="top" rowspan="1" colspan="1">TCCAGTTGACCGCATGGT</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BiADOg-2</td><td align="left" valign="top" rowspan="1" colspan="1">CGAAGGCTTGCTCCCAGT</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><italic>B. angulatum</italic></td><td align="left" valign="top" rowspan="1" colspan="1">BiANG-1</td><td align="left" valign="top" rowspan="1" colspan="1">CAGTCCATCGCATGGTGGT</td><td align="center" valign="top" rowspan="2" colspan="1">65</td><td align="center" valign="top" rowspan="2" colspan="1">II</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BiANG-2</td><td align="left" valign="top" rowspan="1" colspan="1">GAAGGCTTGCTCCCCAAC</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><italic>B. catenulatum or B.
pseudocatenulatum</italic></td><td align="left" valign="top" rowspan="1" colspan="1">BiCAT-1</td><td align="left" valign="top" rowspan="1" colspan="1">CGGATGCTCCGACTCCT</td><td align="center" valign="top" rowspan="2" colspan="1">65</td><td align="center" valign="top" rowspan="2" colspan="1">II</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BiCAT-2</td><td align="left" valign="top" rowspan="1" colspan="1">CGAAGGCTTGCTCCCGAT</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><italic>B. dentium</italic></td><td align="left" valign="top" rowspan="1" colspan="1">BiDEN-1</td><td align="left" valign="top" rowspan="1" colspan="1">ATCCCGGGGGTTCGCCT</td><td align="center" valign="top" rowspan="2" colspan="1">65</td><td align="center" valign="top" rowspan="2" colspan="1">II</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BiDEN-2</td><td align="left" valign="top" rowspan="1" colspan="1">GAAGGGCTTGCTCCCGA</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><italic>B. infantis</italic></td><td align="left" valign="top" rowspan="1" colspan="1">BiINF-1</td><td align="left" valign="top" rowspan="1" colspan="1">TTCCAGTTGATCGCATGGTC</td><td align="center" valign="top" rowspan="2" colspan="1">63</td><td align="center" valign="top" rowspan="2" colspan="1">II</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BiINF-2</td><td align="left" valign="top" rowspan="1" colspan="1">GGAAACCCCATCTCTGGGAT</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><italic>B. lactis</italic></td><td align="left" valign="top" rowspan="1" colspan="1">BlactF</td><td align="left" valign="top" rowspan="1" colspan="1">CCCTTTCCACGGGTCCC</td><td align="center" valign="top" rowspan="2" colspan="1">60</td><td align="center" valign="top" rowspan="2" colspan="1">I</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BlactR</td><td align="left" valign="top" rowspan="1" colspan="1">AAGGGAAACCGTGTCTCCAC</td></tr></tbody></table></table-wrap>, 10 pmol/&#x003bc;l), 2 &#x000b5;l of &#x000d7;1, &#x000d7;10, or &#x000d7;100 diluted DNA template, and 2 &#x000b5;l of distilled water. The
amplification program for <italic>B. lactis</italic>-specific primers consisted of 1 cycle at 95&#x000b0;C for 5 sec,
34 cycles at 95&#x000b0;C for 30 sec, and 1 cycle at 60&#x000b0;C for 30 sec. The amplification program for other primers
consisted of 1 cycle at 94&#x000b0;C for 30 sec, then 35 cycles at 94&#x000b0;C for 20 sec, followed by cycles at 55&#x000b0;C, 63&#x000b0;C,
or 65&#x000b0;C for 30 sec (<xref rid="tbl_001" ref-type="table">Table 1</xref>), and then 1 final cycle at 72&#x000b0;C for
50 sec. Fluorescent products were detected during the final step of each cycle. Melting curve analysis was
performed after amplification to distinguish the targeted and non-targeted PCR products. The melting curves
were obtained by slow heating from 65 to 99&#x000b0;C at a rate of 0.5&#x000b0;C/sec</p><p>Total counts of fecal bifidobacteria were expressed as the sum of the counts of 10 species (namely,
<italic>B. bifidum, B. longum</italic> subsp. <italic>longum, B. adolescentis, B. breve, B. catenulatum, B.
pseudocatenulatum, B. longum</italic> subsp. <italic>infantis, B. anglatum, B. dentium,</italic> and
<italic>B. lactis</italic>).</p></sec><sec><title>Ethics</title><p>These experiments were performed with the approval of the ethical committees of Fuji Women&#x02019;s University
(Experiment 1), and Kenshokai Medical Co., (Osaka, Japan) (Experiment 2). The contents and methods were
explained in full to all prospective subjects, and written informed consent was obtained according to the
principals of the Declaration of Helsinki (adopted in 1964; revised in 1975, 1983, 1989, 1996, and 2000).</p></sec><sec><title>Statistical analysis</title><p>IBM SPSS Statistics for Windows Version 22.0 J (IBM Corp., Armonk, NY, USA) was used for statistical
analyses. Within-group comparisons between the baseline and each subsequent time point were conducted using
repeated-measures ANOVA followed by Dunnett&#x02019;s multiple comparisons. Between-group comparisons of the amount of
change from baseline to each subsequent time point were conducted by one-way ANOVA followed by unpaired
student&#x02019;s t tests. p&#x0003c;0.05 was considered statistically significant, and 0.05 &#x02264; p&#x0003c;0.10 was considered
marginally significant.</p></sec></sec><sec sec-type="results" id="s3"><title>RESULTS</title><sec><title>Short-term changes in fecal bifidobacteria (Experiment 1)</title><p>Three subjects failed to complete the trial due to personal reasons. Eight subjects were excluded from
analysis because of noncompliance with the study requirements, so 53 subjects were analyzed. Background
characteristics for the subjects in Experiment 1 are shown in <xref rid="tbl_002" ref-type="table">Table
2</xref><table-wrap id="tbl_002" orientation="portrait" position="float"><label>Table 2.</label><caption><title> Characteristics of the subjects in Experiment 1</title></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" rowspan="1" colspan="1">Group</td><td align="center" rowspan="1" colspan="1">BL group</td><td align="center" rowspan="1" colspan="1">BB group</td><td align="center" rowspan="1" colspan="1">LBST group</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">20.1 &#x000b1; 1.6</td><td align="center" rowspan="1" colspan="1">20.1 &#x000b1; 1.4</td><td align="center" rowspan="1" colspan="1">20.2 &#x000b1; 1.9</td></tr><tr><td align="left" rowspan="1" colspan="1">The frequency of defecation</td><td align="center" rowspan="1" colspan="1">7.7 &#x000b1; 2.0</td><td align="center" rowspan="1" colspan="1">7.5 &#x000b1; 2.5</td><td align="center" rowspan="1" colspan="1">8.5 &#x000b1; 2.8</td></tr></tbody></table><table-wrap-foot><p>Values are expressed as the mean &#x000b1; SD.</p></table-wrap-foot></table-wrap>. There were no significant differences in any of the characteristics or parameters among the
three groups.</p><p><xref ref-type="fig" rid="fig_003">Figure 3</xref><fig orientation="portrait" fig-type="figure" id="fig_003" position="float"><label>Fig. 3.</label><caption><p> The dynamics of intestinal bifidobacteria following ingestion of <italic>B. lactis</italic> GCL2505
(A), <italic>B. bifidum</italic> GCL2080 (B), or <italic>L. bulgaricus</italic> GCL1031 and <italic>S.
thermophilus</italic> GCL1122 (C).</p><p>Values are expressed as the sum of the mean &#x000b1; SE values of each species. <italic>B. lactis</italic>
GCL2505 ingestion group (BL group), n = 18; <italic>B. bifidum</italic> GCL2080 ingestion group (BB
group), n = 16; <italic>L. bulgaricus</italic> GCL1031 and <italic>S. thermophilus</italic> GCL1122
ingestion group (LBST group), n = 19. Comparisons of the total numbers of fecal bifidobacteria on each
day with those before ingestion are shown. *p&#x0003c;0.05; &#x02020;p&#x0003c;0.1 (Dunnett&#x02019;s multiple comparisons).</p></caption><graphic xlink:href="bmfh-34-077-g003"/></fig> shows the changes in the numbers of fecal bifidobacteria. In the BL group, the total number of
bifidobacteria significantly increased on day 1 compared with before ingestion. The percentage of <italic>B.
lactis</italic> reached nearly 50% of the total amount of bifidobacteria on day 2, and this level was
maintained until day 14. On the other hand, no significant change was observed in the composition and number
of endogenous bifidobacteria in the BL group at the species level throughout the ingestion period. No
significant changes were observed in either the total number of bifidobacteria or the composition of fecal
bifidobacteria in the BB and LBST groups, throughout the ingestion period.</p></sec><sec><title>Long-term changes in the fecal bifidobacteria (Experiment 2)</title><p>Four subjects were excluded from analysis because of noncompliance with the study requirements. Two subjects
were excluded because they had a frequency of defecation of &#x0003e;5.0 times a week during the non-ingestion
period, so 38 subjects were analyzed. Background characteristics for the subjects in Experiment 2 are shown in
<xref rid="tbl_003" ref-type="table">Table 3</xref><table-wrap id="tbl_003" orientation="portrait" position="float"><label>Table 3.</label><caption><title> Characteristics of the subjects in Experiment 2</title></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" rowspan="1" colspan="1">Group</td><td align="center" rowspan="1" colspan="1">Active</td><td align="center" rowspan="1" colspan="1">Placebo</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">40.8 &#x000b1; 7.6</td><td align="center" rowspan="1" colspan="1">42.8 &#x000b1; 7.7</td></tr><tr><td align="left" rowspan="1" colspan="1">The frequency of defecation</td><td align="center" rowspan="1" colspan="1">3.1 &#x000b1; 0.8</td><td align="center" rowspan="1" colspan="1">3.5 &#x000b1; 1.1</td></tr></tbody></table><table-wrap-foot><p>Values are expressed as the mean &#x000b1; SD.</p></table-wrap-foot></table-wrap>. There were no significant differences in any of the characteristics or parameters between the
active and placebo groups.</p><p><xref ref-type="fig" rid="fig_004">Figure 4</xref><fig orientation="portrait" fig-type="figure" id="fig_004" position="float"><label>Fig. 4.</label><caption><p> The dynamics of intestinal bifidobacteria following ingestion of <italic>B. lactis</italic> GCL2505
(+) or placebo milk (&#x02212;).</p><p>Values are expressed as the sum of the mean &#x000b1; SE values of each species. <italic>B. lactis</italic>
GCL2505 ingestion group (active group, +), n = 18; placebo milk ingestion group (placebo group, &#x02212;), n =
19. Comparisons between active and placebo cases at each time point are shown. #p&#x0003c;0.05; &#x02020;p&#x0003c;0.1
(Student&#x02019;s t test).</p></caption><graphic xlink:href="bmfh-34-077-g004"/></fig> shows the changes in the number of fecal bifidobacteria. Before ingestion, there was no difference in
the total amount of fecal bifidobacteria between the two groups. At 2 and 4 weeks after ingestion, the total
number of bifidobacteria significantly increased in the active group compared with the placebo group.
Moreover, the amounts of fecal bifidobacteria in the active group tended to increase 8 weeks after the
ingestion period began compared with the placebo group. However, the total number and the number of each
endogenous <italic>Bifidobacterium</italic> species did not significantly differ between the active and
placebo groups.</p><p>The changes in the frequency of defecation significantly increased in weeks 6 and 8 in the active group
compared with the placebo group (<xref rid="tbl_004" ref-type="table">Table 4</xref><table-wrap id="tbl_004" orientation="portrait" position="float"><label>Table 4.</label><caption><title> Change in the number of defecations</title></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" rowspan="1" colspan="1">Values</td><td align="center" rowspan="1" colspan="1">Groups</td><td align="center" rowspan="1" colspan="1">0 weeks</td><td align="center" rowspan="1" colspan="1">2 weeks</td><td align="center" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">6 weeks</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">8 weks</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" valign="top" rowspan="2" colspan="1">Measured</td><td align="center" valign="top" rowspan="1" colspan="1">Active</td><td align="center" valign="top" rowspan="1" colspan="1">3.1 &#x000b1; 0.8</td><td align="center" valign="top" rowspan="1" colspan="1">4.7 &#x000b1; 2.1</td><td align="center" valign="top" rowspan="1" colspan="1">4.0 &#x000b1; 1.3</td><td align="center" valign="top" rowspan="1" colspan="1">4.9 &#x000b1; 1.6</td><td align="left" rowspan="2" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">4.8 &#x000b1; 1.5</td><td align="left" rowspan="2" colspan="1"/></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">3.5 &#x000b1; 1.1</td><td align="center" valign="top" rowspan="1" colspan="1">4.2 &#x000b1; 1.4</td><td align="center" valign="top" rowspan="1" colspan="1">4.8 &#x000b1; 1.5</td><td align="center" valign="top" rowspan="1" colspan="1">4.1 &#x000b1; 1.3</td><td align="center" valign="top" rowspan="1" colspan="1">3.9 &#x000b1; 1.4</td></tr><tr><td align="left" valign="top" colspan="9" rowspan="1"><hr/></td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Change from 0 weeks</td><td align="center" valign="top" rowspan="1" colspan="1">Active</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="top" rowspan="1" colspan="1">1.6 &#x000b1; 1.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.9 &#x000b1; 1.0</td><td align="center" valign="top" rowspan="1" colspan="1">1.8 &#x000b1; 1.3</td><td align="left" rowspan="2" colspan="1">#</td><td align="center" valign="top" rowspan="1" colspan="1">1.7 &#x000b1; 1.4</td><td align="left" rowspan="2" colspan="1">#</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="top" rowspan="1" colspan="1">0.8 &#x000b1; 1.2</td><td align="center" valign="top" rowspan="1" colspan="1">1.4 &#x000b1; 1.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.7 &#x000b1; 1.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.4 &#x000b1; 1.3</td></tr></tbody></table><table-wrap-foot><p>Values expressed as means &#x000b1; SD. Comparisons between the active and placebo groups at each point are
shown. #p&#x0003c;0.05 (Student&#x02019;s t test).</p></table-wrap-foot></table-wrap>).</p></sec></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>There are many reports on the effects of probiotics on intestinal bifidobacteria [<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>, <xref rid="r26" ref-type="bibr">26</xref>, <xref rid="r27" ref-type="bibr">27</xref>]; however, the effects of consumption of probiotics on the daily dynamics of intestinal
bifidobacteria or ingested probiotics are unclear.</p><p>In Experiment 1, we elucidated the daily dynamics of intestinal bifidobacteria and ingested probiotics.
Ingestion of <italic>B. lactis</italic> GCL2505 increased the total number of intestinal bifidobacteria on day 1
compared with before ingestion, and this level was maintained throughout the ingestion period. According to
species-specific real-time PCR, the fecal cell count for <italic>B. lactis</italic> reached 7.9 &#x000d7; 10<sup>9</sup>
cells/g feces and represented half the population of intestinal bifidobacteria from day 2 onward. On the other
hand, ingestion of <italic>B. bifidum</italic> GCL2080, found to be viable on reaching the intestine in our
preliminary investigation (data not shown), did not lead to significant changes in the total number of
intestinal bifidobacteria, either ingested or endogenous. <italic>B. bifidum</italic> (including ingested
<italic>B. bifidum</italic> GCL2080 and endogenous <italic>B. bifidum</italic>) reached a total of 2.8 &#x000d7;
10<sup>8</sup> cells/g feces and represented a small proportion of the intestinal bifidobacterial microflora
(approximately 2%) following ingestion of <italic>B. bifidum</italic> GCL2080. In addition, no significant
changes were observed in either the composition or numbers of endogenous bifidobacteria at the species level
following ingestion of <italic>L. bulgaricus</italic> GCL1131 and <italic>S. thermophilus</italic> GCL1122.
Nevertheless, lactic acid bacteria from yogurt cultures themselves are also considered probiotics and are
believed to increase intestinal bifidobacterial levels [<xref rid="r28" ref-type="bibr">28</xref>,<xref rid="r29" ref-type="bibr">29</xref>,<xref rid="r30" ref-type="bibr">30</xref>,<xref rid="r31" ref-type="bibr">31</xref>]. These results indicated that the effects of probiotics on the total amount of intestinal
bifidobacteria were strain specific and exerted within a few days of consuming fermented milk produced by
<italic>B. lactis</italic> GCL2505. To the best of our knowledge, this is the first report describing the
daily dynamics of intestinal bifidobacteria, including endogenous and ingested strains, at the species level
during the short-term ingestion of probiotics.</p><p>In Experiment 1, no significant changes were observed in either the composition or numbers of endogenous
bifidobacteria at the species level in any of the three groups. These results suggested that the probiotics had
no effect on the number of endogenous bifidobacteria during short-term ingestion in the healthy human
volunteers. In other words, the increase in the total amount of bifidobacteria was largely attributable to
ingested (exogenous) probiotics. Therefore, the proliferation of ingested probiotics such as <italic>B.
lactis</italic> GCL2505 was an important factor leading to the increase in the total amount of bifidobacteria
in the intestine.</p><p>In most previous studies, the number of intestinal bifidobacteria has been investigated only at the genus level
using cultivation-based techniques [<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>]. In contrast,
we measured the presence of each bifidobacterium species by quantitative PCR in this study to determine accurate
numbers. Moreover, we used species- or subspecies-specific primers to determine the total number of intestinal
bifidobacteria as a sum of the counts of ten species because multiple copy numbers of rRNA operons and genes in
different bacterial chromosomes may affect the apparent relative abundance of bacteria in the sample. For
example, it is reported that <italic>B</italic>. <italic>adolescentis</italic> carries 5 copies of the 16S rRNA
gene [<xref rid="r32" ref-type="bibr">32</xref>], whereas <italic>B. longum</italic> and <italic>B.
lactis</italic> carry 4 and 2 copies of the 16S rRNA gene, respectively [<xref rid="r23" ref-type="bibr">23</xref>, <xref rid="r33" ref-type="bibr">33</xref>,<xref rid="r34" ref-type="bibr">34</xref>,<xref rid="r35" ref-type="bibr">35</xref>]. Therefore, our method of quantifying the total amount of bifidobacteria
gave a more accurate representation than previous culture-based quantification techniques or genus-specific
quantitative PCR. However, the numbers determined by quantitative PCR include both viable and dead cells.
Previously, we revealed that <italic>B. lactis</italic> GCL2505 was detected at the same level in feces on the
day after ingestion by culture-based quantification techniques, followed by PCR identification and
species-specific quantitative PCR [<xref rid="r24" ref-type="bibr">24</xref>]. Therefore, it was considered that
most of the <italic>B. lactis</italic> GCL2505 detected in the present study was in a viable form and
proliferated in the intestine.</p><p>We revealed in our previous study that ingestion of <italic>B. lactis</italic> GCL2505 over 2 weeks
significantly increases the amount of intestinal bifidobacteria and improves the frequency of defecation [<xref rid="r24" ref-type="bibr">24</xref>]. However, the effects of long-term ingestion for more than 2 weeks have
not yet been clarified. Thus, in this study, we investigated the effects of long-term ingestion of <italic>B.
lactis</italic> GCL2505, using the amounts of fecal bifidobacteria and the frequency of defecation as indices
of improvement in the intestinal environment, in addition to the effects resulting from short-term ingestion of
probiotics. During the 8 weeks of <italic>B. lactis</italic> GCL2505 ingestion, the level of intestinal
bifidobacteria and the frequency of defecation significantly increased compared with those in the placebo group.
These results indicated that the effects of <italic>B. lactis</italic> GCL2505 ingestion on the intestinal
microbiota were sustained for at least 8 weeks. On the other hand, the amounts of endogenous bifidobacteria were
not significantly greater after 8 weeks of <italic>B. lactis</italic> GCL2505 ingestion, which showed that even
long-term ingestion of probiotics had no effect on either the number or composition of endogenous
bifidobacteria. In our previous study, ingestion of <italic>B. lactis</italic> GCL2505 over 2 weeks was found to
significantly improve the frequency of defecation [<xref rid="r24" ref-type="bibr">24</xref>]. However, in the
present study, improvements compared with the placebo group were observed only after 6 weeks of intervention.
This is one reason why the present study was designed as a parallel-group trial, in contrast to the cross-over
trial design used in the previous study. A larger sample size was required to reliably detect significant
differences. It was estimated, based on the present data, that a sample size of 118 would be necessary for
detecting significant differences between the active and placebo groups at 2 weeks with 80% power. Overall,
however, ingestion of <italic>B. lactis</italic> GCL2505 increased the frequency of defecation in the active
compared with placebo groups in both the previous and present studies. Therefore, it appears that ingestion of
<italic>B. lactis</italic> GCL2505 is effective against constipation.</p><p>Our results indicated that the proliferation of <italic>B. lactis</italic> GCL2505 in the intestine, which may
cause production of short-chain fatty acids such as acetate and stimulate smooth muscle contractions and
transepithelial chloride secretion [<xref rid="r36" ref-type="bibr">36</xref>,<xref rid="r37" ref-type="bibr">37</xref>,<xref rid="r38" ref-type="bibr">38</xref>,<xref rid="r39" ref-type="bibr">39</xref>,<xref rid="r40" ref-type="bibr">40</xref>,<xref rid="r41" ref-type="bibr">41</xref>,<xref rid="r42" ref-type="bibr">42</xref>,<xref rid="r43" ref-type="bibr">43</xref>], improved the function of the large bowel throughout the
long-term ingestion period.</p><p>In conclusion, we found that <italic>B. lactis</italic> GCL2505 increased the total number of intestinal
bifidobacteria after a few days of ingestion and that long-term ingestion improved the frequency of defecation.
Moreover, we showed that the proliferation of <italic>B. lactis</italic> GCL2505 in the intestine contributed
significantly to the increase in the total number of intestinal bifidobacteria, although there was no
significant change in the amounts of endogenous bifidobacteria. Based on these results, we propose that
probiotics that are able to proliferate in the intestine, such as <italic>B. lactis</italic> GCL2505, appear to
improve the intestinal microbiota more effectively than non-proliferating probiotics.</p></sec></body><back><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="book"><person-group><name><surname>Finegold</surname><given-names>SM</given-names></name><name><surname>Sutter</surname><given-names>VL</given-names></name><name><surname>Matheisen</surname><given-names>GE</given-names></name></person-group><year>1983</year> Normal indigenous flora. <italic>In</italic> Human Intestinal Microflora in
Health and Disease, Hentges DJ (ed), Academic Press, New York, pp. 3&#x02013;31.</mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group><name><surname>Fuller</surname><given-names>R</given-names></name></person-group>
<year>1989</year>
<article-title>Probiotics in man and animals</article-title>. <source>J
Appl Bacteriol</source><volume> 66</volume>: <fpage>365</fpage>&#x02013;<lpage>378</lpage>. <pub-id pub-id-type="pmid">2666378</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Gibson</surname><given-names>GR</given-names></name><name><surname>Roberfroid</surname><given-names>MB</given-names></name></person-group>
<year>1995</year>
<article-title>Dietary modulation of the human colonic microbiota:
introducing the concept of prebiotics</article-title>. <source>J Nutr</source><volume> 125</volume>:
<fpage>1401</fpage>&#x02013;<lpage>1412</lpage>. <pub-id pub-id-type="pmid">7782892</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name><surname>Mitsuoka</surname><given-names>T</given-names></name></person-group>
<year>1984</year>
<article-title>Taxonomy and ecology of bifidobacteria</article-title>.
<source>Bifidobacteria Microflora</source><volume> 3</volume>: <fpage>11</fpage>&#x02013;<lpage>28</lpage>.
</mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="book"><person-group><name><surname>Tanaka</surname><given-names>R</given-names></name></person-group><year>1995</year> Clinical effects of bi&#x0fb01;dobacteria and lactobacilli. <italic>In</italic>
Probiotics: Prospects of Use in Opportunistic Infections, Fuller R, Heidt PJ, Rusch V, Waaij DVD (eds), Old
Herborn University seminar monograph 8. Institute for Microbiology and Biochemistry, Herborn-Dill, Germany,
pp. 141&#x02013;157.</mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Isolauri</surname><given-names>E</given-names></name><name><surname>S&#x000fc;tas</surname><given-names>Y</given-names></name><name><surname>Kankaanp&#x000e4;&#x000e4;</surname><given-names>P</given-names></name><name><surname>Arvilommi</surname><given-names>H</given-names></name><name><surname>Salminen</surname><given-names>S</given-names></name></person-group>
<year>2001</year>
<article-title>Probiotics: effects on immunity</article-title>. <source>Am
J Clin Nutr</source><volume>73</volume>
<issue>Suppl</issue>: <fpage>444S</fpage>&#x02013;<lpage>450S</lpage>. <pub-id pub-id-type="pmid">11157355</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Guarner</surname><given-names>F</given-names></name><name><surname>Malagelada</surname><given-names>JR</given-names></name></person-group>
<year>2003</year>
<article-title>Gut flora in health and disease</article-title>.
<source>Lancet</source><volume> 361</volume>: <fpage>512</fpage>&#x02013;<lpage>519</lpage>. <pub-id pub-id-type="pmid">12583961</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group><name><surname>Nomoto</surname><given-names>K</given-names></name></person-group>
<year>2005</year>
<article-title>Prevention of infections by probiotics</article-title>.
<source>J Biosci Bioeng</source><volume> 100</volume>: <fpage>583</fpage>&#x02013;<lpage>592</lpage>.
<pub-id pub-id-type="pmid">16473765</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group><name><surname>Shioiri</surname><given-names>T</given-names></name><name><surname>Yahagi</surname><given-names>K</given-names></name><name><surname>Nakayama</surname><given-names>S</given-names></name><name><surname>Asahara</surname><given-names>T</given-names></name><name><surname>Yuki</surname><given-names>N</given-names></name><name><surname>Kawakami</surname><given-names>K</given-names></name><name><surname>Yamaoka</surname><given-names>Y</given-names></name><name><surname>Sakai</surname><given-names>Y</given-names></name><name><surname>Nomoto</surname><given-names>K</given-names></name><name><surname>Totani</surname><given-names>M</given-names></name></person-group>
<year>2006</year>
<article-title>The effects of a symbiotic fermented milk beverage
containing <italic>Lactobacillus casei</italic> strain Shirota and transgalactosylated oligosaccharides on
defecation frequency, intestinal microflora, organic acid concentrations, and putrefactive metabolites of
sub-optimal health state volunteers: a randomized placebo-controlled cross-over study</article-title>.
<source>Biosci Microflora</source><volume> 25</volume>: <fpage>137</fpage>&#x02013;<lpage>146</lpage>.
</mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group><name><surname>De Preter</surname><given-names>V</given-names></name><name><surname>Vanhoutte</surname><given-names>T</given-names></name><name><surname>Huys</surname><given-names>G</given-names></name><name><surname>Swings</surname><given-names>J</given-names></name><name><surname>De Vuyst</surname><given-names>L</given-names></name><name><surname>Rutgeerts</surname><given-names>P</given-names></name><name><surname>Verbeke</surname><given-names>K</given-names></name></person-group>
<year>2007</year>
<article-title>Effects of <italic>Lactobacillus casei</italic> Shirota,
<italic>Bifidobacterium breve</italic>, and oligofructose-enriched inulin on colonic nitrogen-protein
metabolism in healthy humans</article-title>. <source>Am J Physiol Gastrointest Liver
Physiol</source><volume> 292</volume>: <fpage>G358</fpage>&#x02013;<lpage>G368</lpage>. <pub-id pub-id-type="pmid">16990449</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="book"><person-group><name><surname>Miyazaki</surname><given-names>K</given-names></name><name><surname>Matsuzaki</surname><given-names>T</given-names></name></person-group><year>2008</year> Health properties of milk fermented with <italic>Lactobacillus
casei</italic> strain Sirota (LcS). <italic>In</italic> Handbook of Fermented Functional Foods, 2nd ed,
Edward RF (ed), CRC Press, Boca Raton, pp. 165&#x02013;172.</mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group><name><surname>Larsen</surname><given-names>CN</given-names></name><name><surname>Nielsen</surname><given-names>S</given-names></name><name><surname>Kaestel</surname><given-names>P</given-names></name><name><surname>Brockmann</surname><given-names>E</given-names></name><name><surname>Bennedsen</surname><given-names>M</given-names></name><name><surname>Christensen</surname><given-names>HR</given-names></name><name><surname>Eskesen</surname><given-names>DC</given-names></name><name><surname>Jacobsen</surname><given-names>BL</given-names></name><name><surname>Michaelsen</surname><given-names>KF</given-names></name></person-group>
<year>2006</year>
<article-title>Dose-response study of probiotic bacteria
<italic>Bifidobacterium animalis</italic> subsp <italic>lactis</italic> BB-12 and <italic>Lactobacillus
paracasei</italic> subsp <italic>paracasei</italic> CRL-341 in healthy young adults</article-title>.
<source>Eur J Clin Nutr</source><volume> 60</volume>: <fpage>1284</fpage>&#x02013;<lpage>1293</lpage>.
<pub-id pub-id-type="pmid">16721394</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Imai</surname><given-names>T</given-names></name><name><surname>Hironaka</surname><given-names>T</given-names></name><name><surname>Kume</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Benno</surname><given-names>Y</given-names></name></person-group>
<year>2000</year>
<article-title>Effect of yogurt with <italic>Bifidobacterium
lactis</italic> LKM 512 in improving fecal microflora and defecation of healthy
volunteers</article-title>. <source>J Ind Microbiol</source><volume> 14</volume>:
<fpage>97</fpage>&#x02013;<lpage>102</lpage>.</mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name><surname>Shimakawa</surname><given-names>Y</given-names></name><name><surname>Matsubara</surname><given-names>S</given-names></name><name><surname>Yuki</surname><given-names>N</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Ishikawa</surname><given-names>F</given-names></name></person-group>
<year>2003</year>
<article-title>Evaluation of <italic>Bifidobacterium breve</italic> strain
Yakult-fermented soymilk as a probiotic food</article-title>. <source>Int J Food Microbiol</source><volume>
81</volume>: <fpage>131</fpage>&#x02013;<lpage>136</lpage>. <pub-id pub-id-type="pmid">12457587</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>Yaeshima</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>N</given-names></name><name><surname>Ishibashi</surname><given-names>N</given-names></name><name><surname>Hayasawa</surname><given-names>H</given-names></name><name><surname>Iino</surname><given-names>H</given-names></name></person-group>
<year>1997</year>
<article-title>Effect of yoghurt containing <italic>Bifidobacterium
longum</italic> BB536 on the intestinal environment, fecal characteristics and defecation
frequency</article-title>. <source>Biosci Microflora</source><volume> 16</volume>:
<fpage>73</fpage>&#x02013;<lpage>77</lpage>. </mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>Hartemink</surname><given-names>R</given-names></name><name><surname>Rombouts</surname><given-names>FM</given-names></name></person-group>
<year>1999</year>
<article-title>Comparison of media for the detection of bifidobacteria,
lactobacilli and total anaerobes from faecal samples</article-title>. <source>J Microbiol
Methods</source><volume> 36</volume>: <fpage>181</fpage>&#x02013;<lpage>192</lpage>. <pub-id pub-id-type="pmid">10379804</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>Martineau</surname><given-names>B</given-names></name></person-group>
<year>1999</year>
<article-title>Comparison of four media for the selection of
bifidobacteria in dog fecal samples</article-title>. <source>Anaerobe</source><volume> 5</volume>:
<fpage>123</fpage>&#x02013;<lpage>127</lpage>. </mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Nebra</surname><given-names>Y</given-names></name><name><surname>Blanch</surname><given-names>AR</given-names></name></person-group>
<year>1999</year>
<article-title>A new selective medium for <italic>Bifidobacterium</italic>
spp</article-title>. <source>Appl Environ Microbiol</source><volume> 65</volume>:
<fpage>5173</fpage>&#x02013;<lpage>5176</lpage>. <pub-id pub-id-type="pmid">10543841</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group><name><surname>Franks</surname><given-names>AH</given-names></name><name><surname>Harmsen</surname><given-names>HJ</given-names></name><name><surname>Raangs</surname><given-names>GC</given-names></name><name><surname>Jansen</surname><given-names>GJ</given-names></name><name><surname>Schut</surname><given-names>F</given-names></name><name><surname>Welling</surname><given-names>GW</given-names></name></person-group>
<year>1998</year>
<article-title>Variations of bacterial populations in human feces measured
by fluorescent in situ hybridization with group-specific 16S rRNA-targeted oligonucleotide
probes</article-title>. <source>Appl Environ Microbiol</source><volume> 64</volume>:
<fpage>3336</fpage>&#x02013;<lpage>3345</lpage>. <pub-id pub-id-type="pmid">9726880</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group><name><surname>Harmsen</surname><given-names>HJ</given-names></name><name><surname>Raangs</surname><given-names>GC</given-names></name><name><surname>He</surname><given-names>T</given-names></name><name><surname>Degener</surname><given-names>JE</given-names></name><name><surname>Welling</surname><given-names>GW</given-names></name></person-group>
<year>2002</year>
<article-title>Extensive set of 16S rRNA-based probes for detection of
bacteria in human feces</article-title>. <source>Appl Environ Microbiol</source><volume> 68</volume>:
<fpage>2982</fpage>&#x02013;<lpage>2990</lpage>. <pub-id pub-id-type="pmid">12039758</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group><name><surname>Langendijk</surname><given-names>PS</given-names></name><name><surname>Schut</surname><given-names>F</given-names></name><name><surname>Jansen</surname><given-names>GJ</given-names></name><name><surname>Raangs</surname><given-names>GC</given-names></name><name><surname>Kamphuis</surname><given-names>GR</given-names></name><name><surname>Wilkinson</surname><given-names>MH</given-names></name><name><surname>Welling</surname><given-names>GW</given-names></name></person-group>
<year>1995</year>
<article-title>Quantitative fluorescence in situ hybridization of
<italic>Bifidobacterium</italic> spp. with genus-specific 16S rRNA-targeted probes and its application in
fecal samples</article-title>. <source>Appl Environ Microbiol</source><volume> 61</volume>:
<fpage>3069</fpage>&#x02013;<lpage>3075</lpage>. <pub-id pub-id-type="pmid">7487040</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group><name><surname>Matsuki</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Fujimoto</surname><given-names>J</given-names></name><name><surname>Takada</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>R</given-names></name></person-group>
<year>2004</year>
<article-title>Use of 16S rRNA gene-targeted group-specific primers for
real-time PCR analysis of predominant bacteria in human feces</article-title>. <source>Appl Environ
Microbiol</source><volume> 70</volume>: <fpage>7220</fpage>&#x02013;<lpage>7228</lpage>. <pub-id pub-id-type="pmid">15574920</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group><name><surname>Satokari</surname><given-names>RM</given-names></name><name><surname>Vaughan</surname><given-names>EE</given-names></name><name><surname>Akkermans</surname><given-names>AD</given-names></name><name><surname>Saarela</surname><given-names>M</given-names></name><name><surname>de Vos</surname><given-names>WM</given-names></name></person-group>
<year>2001</year>
<article-title>Bifidobacterial diversity in human feces detected by
genus-specific PCR and denaturing gradient gel electrophoresis</article-title>. <source>Appl Environ
Microbiol</source><volume> 67</volume>: <fpage>504</fpage>&#x02013;<lpage>513</lpage>. <pub-id pub-id-type="pmid">11157210</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group><name><surname>Ishizuka</surname><given-names>A</given-names></name><name><surname>Tomizuka</surname><given-names>K</given-names></name><name><surname>Aoki</surname><given-names>R</given-names></name><name><surname>Nishijima</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>R</given-names></name><name><surname>Ushida</surname><given-names>K</given-names></name><name><surname>Mawatari</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>T</given-names></name></person-group>
<year>2012</year>
<article-title>Effects of administration of <italic>Bifidobacterium
animalis</italic> subsp. <italic>lactis</italic> GCL2505 on defecation frequency and bifidobacterial
microbiota composition in humans</article-title>. <source>J Biosci Bioeng</source><volume> 113</volume>:
<fpage>587</fpage>&#x02013;<lpage>591</lpage>. <pub-id pub-id-type="pmid">22284965</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group><name><surname>Matsuki</surname><given-names>T</given-names></name></person-group>
<year>2006</year>
<article-title>Procedure of DNA extraction from fecal sample for the
analysis of intestinal microflora</article-title>. <source>Chonai Saikingaku Zasshi</source><volume>
20</volume>: <fpage>259</fpage>&#x02013;<lpage>262</lpage>.</mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Takada</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>K</given-names></name><name><surname>Kado</surname><given-names>Y</given-names></name><name><surname>Kawakami</surname><given-names>K</given-names></name><name><surname>Makino</surname><given-names>I</given-names></name><name><surname>Yamaoka</surname><given-names>Y</given-names></name><name><surname>Hirano</surname><given-names>K</given-names></name><name><surname>Nishimura</surname><given-names>A</given-names></name><name><surname>Kajimoto</surname><given-names>O</given-names></name><name><surname>Nomoto</surname><given-names>K</given-names></name></person-group>
<year>2006</year>
<article-title>The effects of a probiotics milk product containing
<italic>Lactobacillus casei </italic>Shirota on the defecation frequency and the intestinal microflora of
sub-optimal health state volunteers: a randomized placebo-controlled cross-over study</article-title>.
<source>Biosci Microflora</source><volume> 25</volume>: <fpage>39</fpage>&#x02013;<lpage>48</lpage>.
</mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Takada</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>K</given-names></name><name><surname>Moriyama</surname><given-names>K</given-names></name><name><surname>Kawakami</surname><given-names>K</given-names></name><name><surname>Hirano</surname><given-names>K</given-names></name><name><surname>Kajimoto</surname><given-names>O</given-names></name><name><surname>Nomoto</surname><given-names>K</given-names></name></person-group>
<year>2010</year>
<article-title>Effects of a probiotic fermented milk beverage containing
<italic>Lactobacillus casei</italic> strain Shirota on defecation frequency, intestinal microbiota, and
the intestinal environment of healthy individuals with soft stools</article-title>. <source>J Biosci
Bioeng</source><volume> 110</volume>: <fpage>547</fpage>&#x02013;<lpage>552</lpage>. <pub-id pub-id-type="pmid">20580604</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group><name><surname>Mater</surname><given-names>DDG</given-names></name><name><surname>Bretigny</surname><given-names>L</given-names></name><name><surname>Firmesse</surname><given-names>O</given-names></name><name><surname>Flores</surname><given-names>MJ</given-names></name><name><surname>Mogenet</surname><given-names>A</given-names></name><name><surname>Bresson</surname><given-names>JL</given-names></name><name><surname>Corthier</surname><given-names>G</given-names></name></person-group>
<year>2005</year>
<article-title><italic>Streptococcus thermophilus</italic> and
<italic>Lactobacillus delbrueckii</italic> subsp. <italic>bulgaricus</italic> survive gastrointestinal
transit of healthy volunteers consuming yogurt</article-title>. <source>FEMS Microbiol Lett</source><volume>
250</volume>: <fpage>185</fpage>&#x02013;<lpage>187</lpage>. <pub-id pub-id-type="pmid">16099606</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group><name><surname>Guarner</surname><given-names>F</given-names></name><name><surname>Perdigon</surname><given-names>G</given-names></name><name><surname>Corthier</surname><given-names>G</given-names></name><name><surname>Salminen</surname><given-names>S</given-names></name><name><surname>Koletzko</surname><given-names>B</given-names></name><name><surname>Morelli</surname><given-names>L</given-names></name></person-group>
<year>2005</year>
<article-title>Should yoghurt cultures be considered
probiotic?</article-title><source>Br J Nutr</source><volume> 93</volume>:
<fpage>783</fpage>&#x02013;<lpage>786</lpage>. <pub-id pub-id-type="pmid">16022746</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group><name><surname>Lourens-Hattingh</surname><given-names>A</given-names></name><name><surname>Viljoen</surname><given-names>BC</given-names></name></person-group>
<year>2001</year>
<article-title>Yogurt as probiotic carrier food</article-title>.
<source>Int Dairy J</source><volume> 11</volume>: <fpage>1</fpage>&#x02013;<lpage>17</lpage>. </mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group><name><surname>Elli</surname><given-names>M</given-names></name><name><surname>Callegari</surname><given-names>ML</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Bessi</surname><given-names>E</given-names></name><name><surname>Cattivelli</surname><given-names>D</given-names></name><name><surname>Soldi</surname><given-names>S</given-names></name><name><surname>Morelli</surname><given-names>L</given-names></name><name><surname>Goupil Feuillerat</surname><given-names>N</given-names></name><name><surname>Antoine</surname><given-names>JM</given-names></name></person-group>
<year>2006</year>
<article-title>Survival of yogurt bacteria in the human
gut</article-title>. <source>Appl Environ Microbiol</source><volume> 72</volume>:
<fpage>5113</fpage>&#x02013;<lpage>5117</lpage>. <pub-id pub-id-type="pmid">16820518</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group><name><surname>Finegold</surname><given-names>SM</given-names></name><name><surname>Attebery</surname><given-names>HR</given-names></name><name><surname>Sutter</surname><given-names>VL</given-names></name></person-group>
<year>1974</year>
<article-title>Effect of diet on human fecal flora: comparison of Japanese
and American diets</article-title>. <source>Am J Clin Nutr</source><volume> 27</volume>:
<fpage>1456</fpage>&#x02013;<lpage>1469</lpage>. <pub-id pub-id-type="pmid">4432829</pub-id></mixed-citation></ref><ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group><name><surname>Schell</surname><given-names>MA</given-names></name><name><surname>Karmirantzou</surname><given-names>M</given-names></name><name><surname>Snel</surname><given-names>B</given-names></name><name><surname>Vilanova</surname><given-names>D</given-names></name><name><surname>Berger</surname><given-names>B</given-names></name><name><surname>Pessi</surname><given-names>G</given-names></name><name><surname>Zwahlen</surname><given-names>MC</given-names></name><name><surname>Desiere</surname><given-names>F</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Delley</surname><given-names>M</given-names></name><name><surname>Pridmore</surname><given-names>RD</given-names></name><name><surname>Arigoni</surname><given-names>F</given-names></name></person-group>
<year>2002</year>
<article-title>The genome sequence of <italic>Bifidobacterium
longum</italic> reflects its adaptation to the human gastrointestinal tract</article-title>. <source>Proc
Natl Acad Sci USA</source><volume> 99</volume>: <fpage>14422</fpage>&#x02013;<lpage>14427</lpage>. <pub-id pub-id-type="pmid">12381787</pub-id></mixed-citation></ref><ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group><name><surname>Barrangou</surname><given-names>R</given-names></name><name><surname>Briczinski</surname><given-names>EP</given-names></name><name><surname>Traeger</surname><given-names>LL</given-names></name><name><surname>Loquasto</surname><given-names>JR</given-names></name><name><surname>Richards</surname><given-names>M</given-names></name><name><surname>Horvath</surname><given-names>P</given-names></name><name><surname>Co&#x000fb;t&#x000e9;-Monvoisin</surname><given-names>AC</given-names></name><name><surname>Leyer</surname><given-names>G</given-names></name><name><surname>Rendulic</surname><given-names>S</given-names></name><name><surname>Steele</surname><given-names>JL</given-names></name><name><surname>Broadbent</surname><given-names>JR</given-names></name><name><surname>Oberg</surname><given-names>T</given-names></name><name><surname>Dudley</surname><given-names>EG</given-names></name><name><surname>Schuster</surname><given-names>S</given-names></name><name><surname>Romero</surname><given-names>DA</given-names></name><name><surname>Roberts</surname><given-names>RF</given-names></name></person-group>
<year>2009</year>
<article-title>Comparison of the complete genome sequences of
<italic>Bifidobacterium animalis</italic> subsp. <italic>lactis</italic> DSM 10140 and
Bl-04</article-title>. <source>J Bacteriol</source><volume> 191</volume>:
<fpage>4144</fpage>&#x02013;<lpage>4151</lpage>. <pub-id pub-id-type="pmid">19376856</pub-id></mixed-citation></ref><ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group><name><surname>Loquasto</surname><given-names>JR</given-names></name><name><surname>Barrangou</surname><given-names>R</given-names></name><name><surname>Dudley</surname><given-names>EG</given-names></name><name><surname>Stahl</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Roberts</surname><given-names>RF</given-names></name></person-group>
<year>2013</year>
<article-title><italic>Bifidobacterium animalis</italic> subsp.
<italic>lactis</italic> ATCC 27673 is a genomically unique strain within its conserved
subspecies</article-title>. <source>Appl Environ Microbiol</source><volume> 79</volume>:
<fpage>6903</fpage>&#x02013;<lpage>6910</lpage>. <pub-id pub-id-type="pmid">23995933</pub-id></mixed-citation></ref><ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group><name><surname>Kim</surname><given-names>JF</given-names></name><name><surname>Jeong</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>DS</given-names></name><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Hur</surname><given-names>CG</given-names></name><name><surname>Park</surname><given-names>MS</given-names></name><name><surname>Yoon</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Ji</surname><given-names>GE</given-names></name><name><surname>Park</surname><given-names>HS</given-names></name><name><surname>Oh</surname><given-names>TK</given-names></name></person-group>
<year>2009</year>
<article-title>Genome sequence of the probiotic bacterium
<italic>Bifidobacterium animalis</italic> subsp. <italic>lactis</italic> AD011</article-title>. <source>J
Bacteriol</source><volume> 191</volume>: <fpage>678</fpage>&#x02013;<lpage>679</lpage>. <pub-id pub-id-type="pmid">19011029</pub-id></mixed-citation></ref><ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group><name><surname>Ouwehand</surname><given-names>AC</given-names></name><name><surname>Derrien</surname><given-names>M</given-names></name><name><surname>de Vos</surname><given-names>W</given-names></name><name><surname>Tiihonen</surname><given-names>K</given-names></name><name><surname>Rautonen</surname><given-names>N</given-names></name></person-group>
<year>2005</year>
<article-title>Prebiotics and other microbial substrates for gut
functionality</article-title>. <source>Curr Opin Biotechnol</source><volume> 16</volume>:
<fpage>212</fpage>&#x02013;<lpage>217</lpage>. <pub-id pub-id-type="pmid">15831389</pub-id></mixed-citation></ref><ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group><name><surname>Fukumoto</surname><given-names>S</given-names></name><name><surname>Tatewaki</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Fujimiya</surname><given-names>M</given-names></name><name><surname>Mantyh</surname><given-names>C</given-names></name><name><surname>Voss</surname><given-names>M</given-names></name><name><surname>Eubanks</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>M</given-names></name><name><surname>Pappas</surname><given-names>TN</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name></person-group>
<year>2003</year>
<article-title>Short-chain fatty acids stimulate colonic transit via
intraluminal 5-HT release in rats</article-title>. <source>Am J Physiol Regul Integr Comp
Physiol</source><volume> 284</volume>: <fpage>R1269</fpage>&#x02013;<lpage>R1276</lpage>. <pub-id pub-id-type="pmid">12676748</pub-id></mixed-citation></ref><ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group><name><surname>Mitsui</surname><given-names>R</given-names></name><name><surname>Ono</surname><given-names>S</given-names></name><name><surname>Karaki</surname><given-names>S</given-names></name><name><surname>Kuwahara</surname><given-names>A</given-names></name></person-group>
<year>2005</year>
<article-title>Neural and non-neural mediation of propionate-induced
contractile responses in the rat distal colon</article-title>. <source>Neurogastroenterol
Motil</source><volume> 17</volume>: <fpage>585</fpage>&#x02013;<lpage>594</lpage>. <pub-id pub-id-type="pmid">16078948</pub-id></mixed-citation></ref><ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group><name><surname>Mitsui</surname><given-names>R</given-names></name><name><surname>Ono</surname><given-names>S</given-names></name><name><surname>Karaki</surname><given-names>S</given-names></name><name><surname>Kuwahara</surname><given-names>A</given-names></name></person-group>
<year>2005</year>
<article-title>Propionate modulates spontaneous contractions via enteric
nerves and prostaglandin release in the rat distal colon</article-title>. <source>Jpn J
Physiol</source><volume> 55</volume>: <fpage>331</fpage>&#x02013;<lpage>338</lpage>. <pub-id pub-id-type="pmid">16336748</pub-id></mixed-citation></ref><ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group><name><surname>Ono</surname><given-names>S</given-names></name><name><surname>Karaki</surname><given-names>S</given-names></name><name><surname>Kuwahara</surname><given-names>A</given-names></name></person-group>
<year>2004</year>
<article-title>Short-chain fatty acids decrease the frequency of
spontaneous contractions of longitudinal muscle via enteric nerves in rat distal colon</article-title>.
<source>Jpn J Physiol</source><volume> 54</volume>: <fpage>483</fpage>&#x02013;<lpage>493</lpage>. <pub-id pub-id-type="pmid">15667672</pub-id></mixed-citation></ref><ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group><name><surname>Karaki</surname><given-names>S</given-names></name><name><surname>Kuwahara</surname><given-names>A</given-names></name></person-group>
<year>2011</year>
<article-title>Propionate-induced epithelial K(+) and Cl(&#x02013;)/HCO3(&#x02013;)
secretion and free fatty acid receptor 2 (FFA2, GPR43) expression in the guinea pig distal
colon</article-title>. <source>Pflugers Arch</source><volume> 461</volume>:
<fpage>141</fpage>&#x02013;<lpage>152</lpage>. <pub-id pub-id-type="pmid">20945073</pub-id></mixed-citation></ref><ref id="r43"><label>43</label><mixed-citation publication-type="journal"><person-group><name><surname>Yajima</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>R</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Yajima</surname><given-names>M</given-names></name></person-group>
<year>2011</year>
<article-title>Non-neuronal release of ACh plays a key role in secretory
response to luminal propionate in rat colon</article-title>. <source>J Physiol</source><volume>
589</volume>: <fpage>953</fpage>&#x02013;<lpage>962</lpage>. <pub-id pub-id-type="pmid">21135046</pub-id></mixed-citation></ref></ref-list></back></article>